Clinical Trials Logo

Filter by:
NCT ID: NCT03094078 Completed - Clinical trials for The Study Focus on no Specific Condition

Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin by English-speaking Patients

Start date: October 16, 2017
Phase: N/A
Study type: Interventional

The main objective of this study is to compare the interpretation of health news items reporting results of pre-clinical studies with or without spin (i.e., distortion of research results). The news items which reported those studies evaluating the treatment effect either in cell culture studies or animal studies, have high number of spin in the headline and text and received high online public attention will be selected. Spin will be deleted and will rewrite the news items without spin. This sample of news items reporting results of pre-clinical studies with and without spin will be interpreted by English-speaking patients.

NCT ID: NCT03093480 Completed - Clinical trials for Hemophilia A With Inhibitors

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Start date: December 8, 2017
Phase: Phase 4
Study type: Interventional

The primary purpose of this study was to describe the time to tolerization (i.e., ITI success) with rFVIIIFc in participants within a maximum of 48 weeks (12 months) of ITI treatment.

NCT ID: NCT03093337 Completed - Premature Infant Clinical Trials

Psychomotor Therapy for Very Premature Infants

VPI
Start date: December 1, 2007
Phase: N/A
Study type: Interventional

Our current reflexion is that sensory dys-stimulations, including vestibule-proprioceptive disorders and unbalanced between brain and brainstem maturation of the neonatal period involve an early deviant development for immature infants that will be cascaded through the brain scaffolding and later development. The primary purpose is to determine whether the Early Psychomotor Therapy Intervention Program improves development and behavior in very preterm infants (VPI) at 24-month corrected age (CA).

NCT ID: NCT03093259 Completed - Ulcerative Colitis Clinical Trials

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Start date: November 16, 2017
Phase: Phase 2
Study type: Interventional

This Phase IIa study is an 8-week, double-blind, placebo-controlled, randomized study aiming at evaluating the safety and the efficacy of ABX464 given once a day (o.d) at 50 mg in subjects with moderate to severe Active Ulcerative Colitis who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab and/or corticosteroids followed by a one-month follow-up period.

NCT ID: NCT03092700 Completed - COPD Clinical Trials

Pulmonary Rehabilitation, Dyspnoea and Emotional Cognition in COPD

READ-COG BPCO
Start date: April 5, 2017
Phase:
Study type: Observational

To evaluate whether pulmonary rehabilitation improves emotional cognition, using facial emotions recognition and smile production, by improving the emotional dimension of dyspnoea in patients with chronic obstructive pulmonary disease (COPD).To evaluate whether pulmonary rehabilitation improves emotional cognition, using facial emotions recognition and smile production, by improving the emotional dimension of dyspnoea in patients with chronic obstructive pulmonary disease (COPD).

NCT ID: NCT03092583 Completed - Clinical trials for Axial Spondyloarthritis

Analysis of DNA Methylation in Spondyloarthritis

METYLAS
Start date: February 15, 2017
Phase: N/A
Study type: Interventional

The aim of this project is to quantify global DNA methylation in patients with Ankylosing Spondylitis or Axial Spondyloarthritis as compared with control subjects.

NCT ID: NCT03092440 Completed - Education Clinical Trials

Validity Assessment of the "LabForGames Warning" Serious Game

Start date: March 1, 2017
Phase:
Study type: Observational

The use of simulation in medical education has been associated with positive results in the acquisition of knowledge, skills, behaviors and patient outcome. Serious games are useful educational tools since they allow both theory and practice training for an important number of learners, simultaneously. However, few studies have evaluated the validity and effectiveness of serious games. Our simulation unit (LabForSIMS- Faculté de Médecine Paris-Sud, France) has developed a serious game named "LabForGames Warning" for nursing students with the following learning objectives: to recognize and to address the degradation of a patient's clinical condition and to work on the issue of inter-professional communication. The aim of the present study is to determine content and construct validities of the "LabForGames Warning" serious game before its use as a healthcare professional training tool.

NCT ID: NCT03091127 Completed - Multiple Myeloma Clinical Trials

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

Start date: March 14, 2017
Phase:
Study type: Observational

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting. This study will therefore provide essential data to demonstrate the real world utilization of carfilzomib in routine clinical practice, including dosage, administration schedule, regimen, duration of treatment and reason for discontinuation in Europe.

NCT ID: NCT03090854 Completed - Alzheimer Disease Clinical Trials

Cholinergic Markers Alzheimer's Disease

CHOLINE
Start date: November 8, 2017
Phase:
Study type: Observational

Several previous studies have assessed acetylcholine (Ach) and acetylcholinesterase activity (AchE-a) levels in Alzheimer's disease (AD) pathophysiology. The cerebrospinal fluid (CSF) Ach level was significantly decreased in AD patients, and correlated positively with dementia score and MMSE (1, 2). Two studies have demonstrated positive correlations between CSF AchE-a and CSF Tau, phosphorylated-Tau (P-Tau) and AB 1-42 peptide (3,4). ChEIs (cholinesterase inhibitors) have been approved for the treatment of AD but only 20 to 30 % of patients are responders (5). Any consistent data allow the clinician to predict the response to the treatment. The link between basal cholinergic status and ChEIs efficiency has never been done. Even if, there is a wild research in AD treatment, ChEIs or treatment acting on the Ach pathways will remain a long time valuable treatment particularly in moderate AD in which disease modifying therapies did not show any efficiency. The investigators's objective is to prospectively explore the predicting value of CSF Ach and AchE-a levels on ChEIs response in AD patients.

NCT ID: NCT03090724 Completed - Hypertension Clinical Trials

Pharmacokinetics of BIA 5-453 and Its Metabolites

Start date: June 13, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study was to assess the effects of age on the pharmacokinetic (PK) profile of BIA 5-453 and its metabolites.